Copyright Reports & Markets. All rights reserved.

Global Fragile X Syndrome Sales Market Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Global Fragile X Syndrome Sales Market Report 2019

      1 Fragile X Syndrome Market Overview

      • 1.1 Fragile X SyndromeProduct Overview
      • 1.2 Fragile X Syndrome Segment by Type
        • 1.2.1 Global Fragile X Syndrome Sales Comparison by Types (2014-2025)
        • 1.2.2 ACT-01
        • 1.2.3 AMO-01
        • 1.2.4 ANAVEX-273
        • 1.2.5 AUT-00206
        • 1.2.6 Bryostatin-1
        • 1.2.7 Cannabidiol
        • 1.2.8 Others
      • 1.3 Fragile X Syndrome Segment by Application
        • 1.3.1 Global Fragile X Syndrome Sales Comparison by Application (2014-2025)
        • 1.3.1 Clinic
        • 1.3.2 Hopital
        • 1.3.3 Research Center
      • 1.4 Fragile X Syndrome Market by Region
        • 1.4.1 Global Fragile X Syndrome Revenue Comparison by Region (2014-2025)
        • 1.4.2 United States Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.3 Europe Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.4 China Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.5 Japan Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.6 Southeast Asia Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.7 India Fragile X Syndrome Status and Prospect (2014-2025)
      • 1.5 Global Fragile X Syndrome Sales and Revenue (2014-2025)
        • 1.5.1 Global Fragile X Syndrome Sales and Growth Rate (2014-2025)
        • 1.5.2 Global Fragile X Syndrome Revenue and Growth Rate (2014-2025)

      2 Fragile X Syndrome by Company, Region, Type and Application

      • 2.1 Global Fragile X Syndrome Market Competition by Companies
        • 2.1.1 Global Fragile X Syndrome Sales Market Share of Key Companies (2014-2019)
        • 2.1.2 Global Fragile X Syndrome Revenue Market Share by Company (2014-2019)
      • 2.2 Global Fragile X Syndrome Sales and Revenue by Region
        • 2.2.1 Global Fragile X Syndrome Sales Market Share by Region (2014-2019)
        • 2.2.2 Global Fragile X Syndrome Revenue Market Share by Region (2014-2019)
      • 2.3 Global Fragile X Syndrome Sales and Revenue by Type
        • 2.3.1 Global Fragile X Syndrome Sales Market Share by Type (2014-2019)
        • 2.3.2 Global Fragile X Syndrome Revenue Market Share by Type (2014-2019)
      • 2.4 Global Fragile X Syndrome Sales by Application

      3 United States Fragile X Syndrome Sales, Revenue and Price

      • 3.1 United States Fragile X Syndrome Sales and Revenue (2014-2019)
        • 3.1.1 United States Fragile X Syndrome Sales Growth Rate (2014-2019)
        • 3.1.2 United States Fragile X Syndrome Revenue Growth Rate (2014-2019)
        • 3.1.3 United States Fragile X Syndrome Price Trend (2014-2019)
      • 3.2 United States Fragile X Syndrome Sales Market Share by Company
      • 3.3 United States Fragile X Syndrome Sales Market Share by Type
      • 3.4 United States Fragile X Syndrome Sales Market Share by Application

      4 Europe Fragile X Syndrome Sales, Revenue and Price

      • 4.1 Europe Fragile X Syndrome Sales and Value (2014-2019)
        • 4.1.1 Europe Fragile X Syndrome Sales Growth Rate (2014-2019)
        • 4.1.2 Europe Fragile X Syndrome Revenue Growth Rate (2014-2019)
        • 4.1.3 Europe Fragile X Syndrome Price Trend (2014-2019)
      • 4.2 Europe Fragile X Syndrome Sales Market Share by Company
      • 4.3 Europe Fragile X Syndrome Sales Market Share by Type
      • 4.4 Europe Fragile X Syndrome Sales Market Share by Application

      5 China Fragile X Syndrome Sales, Revenue and Price

      • 5.1 China Fragile X Syndrome Sales and Revenue (2014-2019)
        • 5.1.1 China Fragile X Syndrome Sales Growth Rate (2014-2019)
        • 5.1.2 China Fragile X Syndrome Revenue Growth Rate (2014-2019)
        • 5.1.3 China Fragile X Syndrome Price Trend (2014-2019)
      • 5.2 China Fragile X Syndrome Sales Market Share by Company
      • 5.3 China Fragile X Syndrome Sales Market Share by Type
      • 5.4 China Fragile X Syndrome Sales Market Share by Application

      6 Japan Fragile X Syndrome Sales, Revenue and Price

      • 6.1 Japan Fragile X Syndrome Sales and Value (2014-2019)
        • 6.1.1 Japan Fragile X Syndrome Sales Growth Rate (2014-2019)
        • 6.1.2 Japan Fragile X Syndrome Revenue Growth Rate (2014-2019)
        • 6.1.3 Japan Fragile X Syndrome Price Trend (2014-2019)
      • 6.2 Japan Fragile X Syndrome Sales Market Share by Company
      • 6.3 Japan Fragile X Syndrome Sales Market Share by Type
      • 6.4 Japan Fragile X Syndrome Sales Market Share by Application

      7 Southeast Asia Fragile X Syndrome Sales, Revenue and Price

      • 7.1 Southeast Asia Fragile X Syndrome Sales and Value (2014-2019)
        • 7.1.1 Southeast Asia Fragile X Syndrome Sales Growth Rate (2014-2019)
        • 7.1.2 Southeast Asia Fragile X Syndrome Revenue Growth Rate (2014-2019)
        • 7.1.3 Southeast Asia Fragile X Syndrome Price Trend (2014-2019)
      • 7.2 Southeast Asia Fragile X Syndrome Sales Market Share by Company
      • 7.3 Southeast Asia Fragile X Syndrome Sales Market Share by Type
      • 7.4 Southeast Asia Fragile X Syndrome Sales Market Share by Application

      8 India Fragile X Syndrome Sales, Revenue and Price

      • 8.1 India Fragile X Syndrome Sales and Value (2014-2019)
        • 8.1.1 India Fragile X Syndrome Sales Growth Rate (2014-2019)
        • 8.1.2 India Fragile X Syndrome Revenue Growth Rate (2014-2019)
        • 8.1.3 India Fragile X Syndrome Price Trend (2014-2019)
      • 8.2 India Fragile X Syndrome Sales Market Share by Company
      • 8.3 India Fragile X Syndrome Sales Market Share by Type
      • 8.4 India Fragile X Syndrome Sales Market Share by Application

      9 Company Profiles and Key Figures in Fragile X Syndrome Business

      • 9.1 Aelis Farma SAS
        • 9.1.1 Aelis Farma SAS Fragile X Syndrome Production Sites and Area Served
        • 9.1.2 Fragile X Syndrome Specification and Application
        • 9.1.3 Aelis Farma SAS Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.1.4 Main Business and Markets Served
      • 9.2 Alcobra Ltd
        • 9.2.1 Alcobra Ltd Fragile X Syndrome Production Sites and Area Served
        • 9.2.2 Fragile X Syndrome Specification and Application
        • 9.2.3 Alcobra Ltd Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.2.4 Main Business and Markets Served
      • 9.3 AMO Pharma Limited
        • 9.3.1 AMO Pharma Limited Fragile X Syndrome Production Sites and Area Served
        • 9.3.2 Fragile X Syndrome Specification and Application
        • 9.3.3 AMO Pharma Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.3.4 Main Business and Markets Served
      • 9.4 Confluence Pharmaceuticals LLC
        • 9.4.1 Confluence Pharmaceuticals LLC Fragile X Syndrome Production Sites and Area Served
        • 9.4.2 Fragile X Syndrome Specification and Application
        • 9.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.4.4 Main Business and Markets Served
      • 9.5 Eli Lilly and Company
        • 9.5.1 Eli Lilly and Company Fragile X Syndrome Production Sites and Area Served
        • 9.5.2 Fragile X Syndrome Specification and Application
        • 9.5.3 Eli Lilly and Company Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.5.4 Main Business and Markets Served
      • 9.6 F. Hoffmann-La Roche Ltd.
        • 9.6.1 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Production Sites and Area Served
        • 9.6.2 Fragile X Syndrome Specification and Application
        • 9.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.6.4 Main Business and Markets Served
      • 9.7 Marinus Pharmaceuticals, Inc.
        • 9.7.1 Marinus Pharmaceuticals, Inc. Production Sites and Area Served
        • 9.7.2 Fragile X Syndrome Specification and Application
        • 9.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.7.4 Main Business and Markets Served
      • 9.8 MI.TO. Technology S.r.L.
        • 9.8.1 MI.TO. Technology S.r.L. Fragile X Syndrome Production Sites and Area Served
        • 9.8.2 Fragile X Syndrome Specification and Application
        • 9.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.8.4 Main Business and Markets Served
      • 9.9 Neuren Pharmaceuticals Limited
        • 9.9.1 Neuren Pharmaceuticals Limited Fragile X Syndrome Production Sites and Area Served
        • 9.9.2 Fragile X Syndrome Specification and Application
        • 9.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.9.4 Main Business and Markets Served
      • 9.10 Ovid Therapeutics Inc.
        • 9.10.1 Ovid Therapeutics Inc. Fragile X Syndrome Production Sites and Area Served
        • 9.10.2 Fragile X Syndrome Specification and Application
        • 9.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2014-2019)
        • 9.10.4 Main Business and Markets Served
      • 9.11 Sage Therapeutics, Inc.
      • 9.12 Zynerba Pharmaceuticals, Inc.

      10 Fragile X Syndrome Maufacturing Cost Analysis

      • 10.1 Fragile X Syndrome Key Raw Materials Analysis
        • 10.1.1 Key Raw Materials
        • 10.1.2 Key Raw Materials Price Trend
        • 10.1.3 Key Suppliers of Raw Materials
      • 10.2 Proportion of Manufacturing Cost Structure
      • 10.3 Manufacturing Process Analysis of Fragile X Syndrome
      • 10.4 Fragile X Syndrome Industrial Chain Analysis

      11 Marketing Channel, Distributors and Customers

      • 11.1 Marketing Channel
        • 11.1.1 Direct Marketing
        • 11.1.2 Indirect Marketing
      • 11.2 Fragile X Syndrome Distributors List
      • 11.3 Fragile X Syndrome Customers

      12 Market Dynamics

      • 12.1 Market Trends
      • 12.2 Opportunities
      • 12.3 Market Drivers
      • 12.4 Challenges
      • 12.5 Influence Factors

      13 Fragile X Syndrome Market Forecast

      • 13.1 Global Fragile X Syndrome Sales, Revenue and Price Forecast
        • 13.1.1 Global Fragile X Syndrome Sales Growth Forecast (2019-2025)
        • 13.1.2 Global Fragile X Syndrome Revenue Growth Forecast (2019-2025)
        • 13.1.3 Global Fragile X Syndrome Price Trend Forecast (2019-2025)
      • 13.2 Global Fragile X Syndrome Forecast by Region
        • 13.2.1 Global Fragile X Syndrome Sales Growth Forecast by Region (2019-2025)
        • 13.2.2 Global Fragile X Syndrome Revenue Growth Forecast by Region (2019-2025)
        • 13.2.3 United States Fragile X Syndrome Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.4 Europe Fragile X Syndrome Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.5 China Fragile X Syndrome Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.6 Japan Fragile X Syndrome Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.7 Southeast Asia Fragile X Syndrome Sales, Revenue Growth Forecast (2019-2025)
        • 13.2.8 India Fragile X Syndrome Sales, Revenue Growth Forecast (2019-2025)
      • 13.3 Global Fragile X Syndrome Forecast by Type
        • 13.3.1 Global Fragile X Syndrome Sales Forecast by Type (2019-2025)
        • 13.3.2 Global Fragile X Syndrome Revenue Forecast by Type (2019-2025)
        • 13.3.3 Global Fragile X Syndrome Price Forecast by Type (2019-2025)
      • 13.4 Global Fragile X Syndrome Forecast by Application

      14 Research Findings and Conclusion

        15 Methodology and Data Source

        • 15.1 Methodology/Research Approach
          • 15.1.1 Research Programs/Design
          • 15.1.2 Market Size Estimation
          • 15.1.3 Market Breakdown and Data Triangulation
        • 15.2 Data Source
          • 15.2.1 Secondary Sources
          • 15.2.2 Primary Sources
        • 15.3 Author List

        The global Fragile X Syndrome market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report studies the global Fragile X Syndrome market status and forecast, categorizes the global Fragile X Syndrome market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

        Major manufacturers covered in this report
        Aelis Farma SAS
        Alcobra Ltd
        AMO Pharma Limited
        Confluence Pharmaceuticals LLC
        Eli Lilly and Company
        F. Hoffmann-La Roche Ltd.
        Marinus Pharmaceuticals, Inc.
        MI.TO. Technology S.r.L.
        Neuren Pharmaceuticals Limited
        Ovid Therapeutics Inc.
        Sage Therapeutics, Inc.
        Zynerba Pharmaceuticals, Inc.

        In view of regional level, this report covers
        United States
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        ACT-01
        AMO-01
        ANAVEX-273
        AUT-00206
        Bryostatin-1
        Cannabidiol
        Others

        Segment by Application
        Clinic
        Hopital
        Research Center

        Buy now